Adane Anmaw Mengesha, one of Ethiopia’s rising road-running talents, has been handed a five-year ban after a series of anti-doping rule violations that began with an intravenous treatment and spiraled into a tampering case.
The 22-year-old from Oromia, who finished second at the Cherry Blossom 10 Miler in Washington D.C. on April 4, 2025, admitted using an amino acid solution delivered via IV infusion on the day of the race. That declaration during sample collection opened the door to a deeper investigation by USADA.
What they found went far beyond a single drip.
Between March 26 and March 30, 2025, Mengesha received multiple intravenous infusions exceeding 100 mL in any 12‑hour period, prescribed by a doctor to treat a medical condition. On the surface, that might sound like routine medical care. Under anti-doping rules, it is anything but.
Any IV infusions or injections totaling more than 100 mL per 12 hours are classified as a Specified Method and banned at all times, unless they occur during hospital treatment, surgery, or a clinical diagnostic investigation, or fall under a specific exemption. No prohibited substances were found in Mengesha’s treatment, yet the volume alone pushed it over the legal line set by the World Anti-Doping Code and the WADA Prohibited List, adopted in the USADA Protocol, the United States Olympic and Paralympic Committee policies, and the World Athletics Anti-Doping Rules.
That was the first blow. The second did more damage.
Working with the Ethiopian Anti-Doping Authority (ETH-ADA), investigators determined that Mengesha went on to commit tampering when she applied for a Therapeutic Use Exemption. As an Ethiopian athlete, she was required to submit her TUE request to ETH-ADA. In that application, she provided falsified documents claiming the infusions had been administered at a hospital in Addis Ababa.
The paperwork didn’t hold up. The forged hospital records not only failed to justify the treatment, they also triggered a separate violation for tampering with the results management process, dragging out the investigation and hardening the eventual sanction.
Under Article 10.8.1 of the Code, athletes facing a potential ban of four years or more can earn a one-year reduction if they admit the violation and accept the sanction within 20 days of being charged. Mengesha did so, trimming her penalty from an otherwise asserted six-year suspension down to five.
Her period of ineligibility is dated from November 5, 2025, the day she was provisionally suspended. Every result from April 4, 2025 onward, including that runner-up finish in Washington, is now wiped from the books, with all medals, points, and prize money forfeited.
The case underlines a familiar fault line in modern athletics: medical treatment on one side, strict procedural and volume limits on the other. Cross that line without proper authorization, then attempt to cover the tracks, and the sanction quickly escalates from a technical breach to a career-altering ban.
USADA, which oversees testing and results management for athletes in the U.S. Olympic and Paralympic Movement, continues to lean heavily on education to prevent exactly this kind of scenario. It offers detailed guidance on prohibited methods and substances, Whereabouts obligations, TUE procedures, and the dangers of supplements and performance-enhancing drugs, backed by online resources, a drug reference hotline, Global Drug Reference Online, and regular educational sessions with national governing bodies.
It also maintains multiple reporting channels for tips on doping abuse, from its Play Clean Tip Center to text, email, phone, and mail options, all aimed at shielding clean athletes and protecting the integrity of competition.
For Mengesha, the message arrived too late. For the rest of the elite road-running circuit, the warning could not be clearer: in a system that polices not only what goes into an athlete’s body but how and where it is delivered, there is no hiding behind paperwork when the drip bag tells a different story.
